2 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

GCC-targeted CAR-T cells show activity in heavily pretreated metastatic CRC
A phase 1 trial of 24 patients with metastatic colorectal cancer who received at least two prior lines of treatment tested GCC-targeted CAR-T cells at four dose levels. All patients experienced grade 3 or higher hematologic toxicity, 75% developed cytokine release syndrome, and two treatment-related deaths occurred. (Clin Cancer Res)
Survivors of CRS-HIPEC for peritoneal metastases report functional outcomes
A cross-sectional study of 100 survivors (59 with colorectal cancer with peritoneal metastasis, 41 with pseudomyxoma peritonei) assessed functional and participation outcomes at a mean of 2.4 years after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. (Adv Rehabil Sci Pract)
Review examines anti-VEGF plus checkpoint inhibitor combinations in GI cancers
A narrative review synthesizes preclinical and clinical data on combining anti-VEGF agents with immune checkpoint inhibitors across gastrointestinal cancers, including colorectal cancer, with emphasis on optimal sequencing strategies. (Discov Oncol)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

Meta-analysis projects rising early-onset CRC burden through 2030
A systematic review and meta-analysis evaluated early-onset colorectal cancer (diagnosed under age 50) incidence and temporal trends from 1990 to 2021, identifying associated risk factors and projecting burden through 2030. (Cureus)
Alabama study examines lifestyle and metabolic factors in early- vs late-onset CRC
A retrospective study from 2010–2023 investigated whether associations between lifestyle factors (smoking, BMI) and clinical factors (type 2 diabetes, hypertension, hyperlipidemia) and age at CRC diagnosis differed by race. (Cancer Causes Control)

Research continues to advance our understanding of treatment options, early-onset disease, and the tumor microenvironment. Stay informed and discuss new findings with your care team.

Get CRC research intelligence delivered weekly — free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues